Quasispecies and its impact on viral hepatitis

Virus Research

Volumn 127, Issue 2, 2007, Pages 131-150

  Domingo, Esteban ^a   Gomez, Jordi ^b  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

Author keywords

Editing; Error catastrophe; HAV; HBV; HCV; HDV; Immune escape; Interferon; Lamivudine; Lethal mutagenesis; Liver damage; Mutation; Persistence; Recombination; Viral load

Indexed keywords

ALPHA INTERFERON; FLUOROURACIL; INTERFERON; MONOCLONAL ANTIBODY; PEGINTERFERON; RIBAVIRIN;

ARTICLE; DNA REPLICATION; DRUG MECHANISM; FOOT AND MOUTH DISEASE VIRUS; GENETIC VARIABILITY; HUMAN; IMMUNE RESPONSE; MONOTHERAPY; MUTAGENESIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RNA FINGERPRINTING; RNA REPAIR; RNA REPLICATION; RNA VIRUS; SPECIES COMPARISON; TREATMENT RESPONSE; VIRUS HEPATITIS; VIRUS MUTATION; VIRUS VIRULENCE;

ANTIVIRAL AGENTS; GENOME, VIRAL; HEPATITIS; HEPATITIS VIRUSES; HUMANS; MUTATION; RIBAVIRIN; SELECTION (GENETICS); VARIATION (GENETICS);

HEPATITIS A VIRUS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; RNA VIRUSES;

EID: 34447320468     PISSN: 01681702     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.virusres.2007.02.001     Document Type: Article

References (224)

1. Abe K., Inchauspe G., and Fujisawa K. Genomic characterization and mutation rate of hepatitis C virus isolated from a patient who contracted hepatitis during an epidemic of non-A, non-B hepatitis in Japan. J. Gen. Virol. 73 (1992) 2725-2729
2. Agol V.I. Molecular mechanisms of poliovirus variation and evolution. Curr. Top. Microbiol. Immunol. 299 (2006) 211-259
3. Airaksinen A., Pariente N., Menendez-Arias L., and Domingo E. Curing of foot-and-mouth disease virus from persistently infected cells by ribavirin involves enhanced mutagenesis. Virology 311 2 (2003) 339-349
4. Allen M.I., Deslauriers M., Andrews C.W., Tipples G.A., Walters K.A., Tyrrell D.L., Brown N., and Condreay L.D. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 27 6 (1998) 1670-1677
5. Anderson J.P., Daifuku R., and Loeb L.A. Viral error catastrophe by mutagenic nucleosides. Annu. Rev. Microbiol. 58 (2004) 183-205
6. Arnold J.J., Ghosh S.K., and Cameron C.E. Poliovirus RNA-dependent RNA polymerase (3D(pol)). Divalent cation modulation of primer, template, and nucleotide selection. J. Biol. Chem. 274 52 (1999) 37060-37069
7. Arnold J.J., Vignuzzi M., Stone J.K., Andino R., and Cameron C.E. Remote site control of an active site fidelity checkpoint in a viral RNA-dependent RNA polymerase. J. Biol. Chem. 280 27 (2005) 25706-25716
8. Asahina Y., Izumi N., Enomoto N., Uchihara M., Kurosaki M., Onuki Y., Nishimura Y., Ueda K., Tsuchiya K., Nakanishi H., Kitamura T., and Miyake S. Mutagenic effects of ribavirin and response to interferon/ribavirin combination therapy in chronic hepatitis C. J. Hepatol. 43 4 (2005) 623-629
9. Bartholomeusz A., and Locarnini S. Hepatitis B virus mutations associated with antiviral therapy. J. Med. Virol. 78 Suppl 1 (2006) S52-S55
10. Bartholomeusz A., and Locarnini S.A. Antiviral drug resistance: clinical consequences and molecular aspects. Semin. Liver Dis. 26 2 (2006) 162-170
11. Batschelet E., Domingo E., and Weissmann C. The proportion of revertant and mutant phage in a growing population, as a function of mutation and growth rate. Gene 1 1 (1976) 27-32
12. Biebricher C.K., and Eigen M. The error threshold. Virus Res. 107 2 (2005) 117-127
13. Biebricher C.K., and Eigen M. What is a quasispecies?. Curr. Top. Microbiol. Immunol. 299 (2006) 1-31
14. Boerlijst M.C., Boenhoefer S., and Nowak M.A. Viral quasispecies and recombination. Proc. R. Soc. Lond. B 263 (1996) 1577-1584
15. Bollyky P.L., Rambaut A., Harvey P.H., and Holmes E.C. Recombination between sequences of hepatitis B virus from different genotypes. J. Mol. Evol. 42 2 (1996) 97-102
16. Bonhoeffer S., May R.M., Shaw G.M., and Nowak M.A. Virus dynamics and drug therapy. Proc. Natl. Acad. Sci. U.S.A. 94 13 (1997) 6971-6976
17. Bonvin M., Achermann F., Greeve I., Stroka D., Keogh A., Inderbitzin D., Candinas D., Sommer P., Wain-Hobson S., Vartanian J.P., and Greeve J. Interferon-inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication. Hepatology 43 6 (2006) 1364-1374
18. Borrow P., Lewicki H., Wei X., Horwitz M.S., Peffer N., Meyers H., Nelson J.A., Gairin J.E., Hahn B.H., Oldstone M.B., and Shaw G.M. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat. Med. 3 2 (1997) 205-211
19. Bowen D.G., and Walker C.M. The origin of quasispecies: cause or consequence of chronic hepatitis C viral infection?. J. Hepatol. 42 3 (2005) 408-417
20. Bowen D.G., McCaughan G.W., and Bertolino P. Intrahepatic immunity: a tale of two sites?. Trends Immunol. 26 10 (2005) 512-517
21. Briones C., Domingo E., and Molina-París C. Memory in retroviral quasispecies: experimental evidence and theoretical model for human immunodeficiency virus. J. Mol. Biol. 331 1 (2003) 213-229
22. Cabot B., Martell M., Esteban J.I., Sauleda S., Otero T., Esteban R., Guardia J., and Gomez J. Nucleotide and amino acid complexity of hepatitis C virus quasispecies in serum and liver. J. Virol. 74 2 (2000) 805-811
23. Cabot B., Martell M., Esteban J.I., Piron M., Otero T., Esteban R., Guardia J., and Gómez J. Longitudinal evaluation of the structure of replicating and circulating hepatitis C virus quasispecies in nonprogressive chronic hepatitis C patients. J. Virol. 75 24 (2001) 12005-12013
24. Chambers T.J., Fan X., Droll D.A., Hembrador E., Slater T., Nickells M.W., Dustin L.B., and Dibisceglie A.M. Quasispecies heterogeneity within the E1/E2 region as a pretreatment variable during pegylated interferon therapy of chronic hepatitis C virus infection. J. Virol. 79 5 (2005) 3071-3083
25. Chang K.M., Rehermann B., McHutchison J.G., Pasquinelli C., Southwood S., Sette A., and Chisari F.V. Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus. J. Clin. Invest. 100 9 (1997) 2376-2385
26. Cheng C.P., Serviene E., and Nagy P.D. Suppression of viral RNA recombination by a host exoribonuclease. J. Virol. 80 6 (2006) 2631-2640
27. Chetverin A.B., Kopein D.S., Chetverina H.V., Demidenko A.A., and Ugarov V.I. Viral RNA-directed RNA polymerases use diverse mechanisms to promote recombination between RNA molecules. J. Biol. Chem. 280 10 (2005) 8748-8755
28. Chiu Y.L., and Greene W.C. Multifaceted antiviral actions of APOBEC3 cytidine deaminases. Trends Immunol. 27 6 (2006) 291-297
29. Chohan B., Lavreys L., Rainwater S.M., and Overbaugh J. Evidence for frequent reinfection with human immunodeficiency virus type 1 of a different subtype. J. Virol. 79 16 (2005) 10701-10708
30. Cicin-Sain L., Podlech J., Messerle M., Reddehase M.J., and Koszinowski U.H. Frequent coinfection of cells explains functional in vivo complementation between cytomegalovirus variants in the multiply infected host. J. Virol. 79 15 (2005) 9492-9502
31. Ciurea A., Hunziker L., Martinic M.M., Oxenius A., Hengartner H., and Zinkernagel R.M. CD4+ T-cell-epitope escape mutant virus selected in vivo. Nat. Med. 7 7 (2001) 795-800
32. Clementi M. Intra-host genetic heterogeneity of hepatitis C virus and biomedical implications. J. Biol. Regul. Homeost. Agents 17 2 (2003) 120-124
33. Coffin J.M. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267 5197 (1995) 483-489
34. Contreras A.M., Hiasa Y., He W., Terella A., Schmidt E.V., and Chung R.T. Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system. J. Virol. 76 17 (2002) 8505-8517
35. Cooper S., Erickson A.L., Adams E.J., Kansopon J., Weiner A.J., Chien D.Y., Houghton M., Parham P., and Walker C.M. Analysis of a successful immune response against hepatitis C virus. Immunity 10 4 (1999) 439-449
36. Costa-Mattioli M., Ferre V., Casane D., Perez-Bercoff R., Coste-Burel M., Imbert-Marcille B.M., Andre E.C., Bressollette-Bodin C., Billaudel S., and Cristina J. Evidence of recombination in natural populations of hepatitis A virus. Virology 311 1 (2003) 51-59
37. Cristina J., and Colina R. Evidence of structural genomic region recombination in Hepatitis C virus. Virol. J. 3 (2006) 53
38. Crotty S., Maag D., Arnold J.J., Zhong W., Lau J.Y.N., Hong Z., Andino R., and Cameron C.E. The broad-spectrum antiviral ribonucleotide, ribavirin, is an RNA virus mutagen. Nat. Med. 6 (2000) 1375-1379
39. Crotty S., Cameron C.E., and Andino R. RNA virus error catastrophe: direct molecular test by using ribavirin. Proc. Natl. Acad. Sci. U.S.A. 98 12 (2001) 6895-6900
40. Dawson T.R., Sansam C.L., and Emeson R.B. Structure and sequence determinants required for the RNA editing of ADAR2 substrates. J. Biol. Chem. 279 6 (2004) 4941-4951
41. de la Torre J.C., and Holland J.J. RNA virus quasispecies populations can suppress vastly superior mutant progeny. J. Virol. 64 12 (1990) 6278-6281
42. Deforges S., Evlashev A., Perret M., Sodoyer M., Pouzol S., Scoazec J.Y., Bonnaud B., Diaz O., Paranhos-Baccala G., Lotteau V., and Andre P. Expression of hepatitis C virus proteins in epithelial intestinal cells in vivo. J. Gen. Virol. 85 Pt 9 (2004) 2515-2523
43. Delaney W.E.T., Yang H., Westland C.E., Das K., Arnold E., Gibbs C.S., Miller M.D., and Xiong S. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J. Virol. 77 21 (2003) 11833-11841
44. Domingo E. RNA virus evolution and the control of viral disease. Prog. Drug Res. 33 (1989) 93-133
45. Domingo E. Quasispecies and the development of new antiviral strategies. Prog. Drug Res. 60 (2003) 133-158
46. Domingo, E., (Ed.), 2005. Virus entry into error catastrophe as a new antiviral strategy. Virus Res. 107, 115-228.
47. Domingo, E., (Ed.), 2006. Quasispecies: concepts and implications for virology. Curr. Top. Microbiol. Immunol. 299.
48. Domingo, E., 2007. Virus Evolution, in: Knipe, D.M., Howley, P.M., (Eds.), Fields Virology, in press.
49. Domingo E., and Holland J.J. Complications of RNA heterogeneity for the engineering of virus vaccines and antiviral agents. Genet. Eng. (N.Y.) 14 (1992) 13-31
50. Domingo E., Biebricher C., Eigen M., and Holland J.J. Quasispecies and RNA Virus Evolution: Principles and Consequences (2001), Landes Bioscience, Austin
51. Domingo E., Martin V., Perales C., Grande-Perez A., Garcia-Arriaza J., and Arias A. Viruses as quasispecies: biological implications. Curr. Top. Microbiol. Immunol. 299 (2006) 51-82
52. Drake J.W., and Holland J.J. Mutation rates among RNA viruses. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 13910-13913
53. Earl D.J., and Deem M.W. Evolvability is a selectable trait. Proc. Natl. Acad. Sci. U.S.A. 101 32 (2004) 11531-11536
54. Eigen M. New concepts for dealing with the evolution of nucleic acids. Cold Spring Harb. Symp. Quant. Biol. 52 (1987) 307-320
55. Eigen M. Natural selection: a phase transition?. Biophys. Chem. 85 (2000) 101-123
56. Eigen M. Error catastrophe and antiviral strategy. Proc. Natl. Acad. Sci. U.S.A. 99 21 (2002) 13374-13376
57. Eigen M., and Biebricher C.K. Sequence space and quasispecies distribution. In: Domingo E., Ahlquist P., and Holland J.J. (Eds). RNA Genetics 3 (1988), CRC Press, Boca Raton, FL
58. Eigen M., and Schuster P. The hypercycle. A principle of natural self-organization (1979), Springer, Berlin
59. Enomoto N., Kurosaki M., Tanaka Y., Marumo F., and Sato C. Fluctuation of hepatitis C virus quasispecies in persistent infection and interferon treatment revealed by single-strand conformation polymorphism analysis. J. Gen. Virol. 75 Pt 6 (1994) 1361-1369
60. Enomoto N., Sakuma I., Asahina Y., Kurosaki M., Murakami T., Yamamoto C., Izumi N., Marumo F., and Sato C. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J. Clin. Invest. 96 1 (1995) 224-230
61. Eren R., Landstein D., Terkieltaub D., Nussbaum O., Zauberman A., Ben-Porath J., Gopher J., Buchnick R., Kovjazin R., Rosenthal-Galili Z., Aviel S., Ilan E., Shoshany Y., Neville L., Waisman T., Ben-Moshe O., Kischitsky A., Foung S.K., Keck Z.Y., Pappo O., Eid A., Jurim O., Zamir G., Galun E., and Dagan S. Preclinical evaluation of two neutralizing human monoclonal antibodies against hepatitis C virus (HCV): a potential treatment to prevent HCV reinfection in liver transplant patients. J. Virol. 80 6 (2006) 2654-2664
62. Erickson A.L., Kimura Y., Igarashi S., Eichelberger J., Houghton M., Sidney J., McKinney D., Sette A., Hughes A.L., and Walker C.M. The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity 15 6 (2001) 883-895
63. Escarmís C., Lázaro E., and Manrubia S.C. Population bottlenecks in quasispecies dynamics. Curr. Top. Microbiol. Immunol. 299 (2006) 141-170
64. Esteban J.I., Gómez J., Martell M., and Guardia J. Hepatitis C Virus. In: Wilson R.A. (Ed). Viral Hepatitis (1997), Marcel Dekker, New York
65. Esteban J.I., Martell M., Carman W.F., and Gomez J. The impact of rapid evolution of the hepatitis viruses. In: Domingo E., Webster R.G., and Holland J.J. (Eds). Origin and Evolution of Viruses (1999), Academic Press, San Diego
66. Farci P., Shimoda A., Coiana A., Diaz G., Peddis G., Melpolder J.C., Strazzera A., Chien D.Y., Munoz S.J., Balestrieri A., Purcell R.H., and Alter H.J. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 288 5464 (2000) 339-344
67. Farci P., Strazzera R., Alter H.J., Farci S., Degioannis D., Coiana A., Peddis G., Usai F., Serra G., Chessa L., Diaz G., Balestrieri A., and Purcell R.H. Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. Proc. Natl. Acad. Sci. U.S.A. 99 5 (2002) 3081-3086
68. Farci P., Quinti I., Farci S., Alter H.J., Strazzera R., Palomba E., Coiana A., Cao D., Casadei A.M., Ledda R., Iorio R., Vegnente A., Diaz G., and Tovo P.A. Evolution of hepatitis C viral quasispecies and hepatic injury in perinatally infected children followed prospectively. Proc. Natl. Acad. Sci. U.S.A. 103 22 (2006) 8475-8480
69. Ferrer-Orta C., Arias A., Escarmis C., and Verdaguer N. A comparison of viral RNA-dependent RNA polymerases. Curr. Opin. Struct. Biol. 16 1 (2006) 27-34
70. Figlerowicz M., Alejska M., Kurzynska-Kokorniak A., and Figlerowicz M. Genetic variability: the key problem in the prevention and therapy of RNA-based virus infections. Med. Res. Rev. 23 4 (2003) 488-518
71. Forton D.M., Karayiannis P., Mahmud N., Taylor-Robinson S.D., and Thomas H.C. Identification of unique hepatitis C virus quasispecies in the central nervous system and comparative analysis of internal translational efficiency of brain, liver, and serum variants. J. Virol. 78 10 (2004) 5170-5183
72. Franco S., Gimenez-Barcons M., Puig-Basagoiti F., Furcic I., Sanchez-Tapias J.M., Rodes J., and Saiz J.C. Characterization and evolution of NS5A quasispecies of hepatitis C virus genotype 1b in patients with different stages of liver disease. J. Med. Virol. 71 2 (2003) 195-204
73. Friedberg E.C., Walker G.C., Siede W., Wood R.D., Schultz R.A., and Ellenberger T. DNA Repair and Mutagenesis (2006), American Society for Microbiology, Washington, DC
74. Friedrich T.C., Dodds E.J., Yant L.J., Vojnov L., Rudersdorf R., Cullen C., Evans D.T., Desrosiers R.C., Mothe B.R., Sidney J., Sette A., Kunstman K., Wolinsky S., Piatak M., Lifson J., Hughes A.L., Wilson N., O'Connor D.H., and Watkins D.I. Reversion of CTL escape-variant immunodeficiency viruses in vivo. Nat. Med. 10 3 (2004) 275-281
75. Fu L., and Cheng Y.C. Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance. Biochem. Pharmacol. 55 10 (1998) 1567-1572
76. Gallei A., Pankraz A., Thiel H.J., and Becher P. RNA recombination in vivo in the absence of viral replication. J. Virol. 78 12 (2004) 6271-6281
77. Gaudy C., Lambele M., Moreau A., Veillon P., Lunel F., and Goudeau A. Mutations within the hepatitis C virus genotype 1b E2-PePHD domain do not correlate with treatment outcome. J. Clin. Microbiol. 43 2 (2005) 750-754
78. Gauss-Muller V., and Kusov Y.Y. Replication of a hepatitis A virus replicon detected by genetic recombination in vivo. J. Gen. Virol. 83 Pt 9 (2002) 2183-2192
79. Giménez-Barcons M., Ibañez A., Tajahuerce A., Sánchez-Tapias J.M., Rodes J., Martinez M.A., and Saiz J.C. Genetic evolution of hepatitis G virus in chronically infected individual patients. J. Gen. Virol. 79 (1998) 2623-2629
80. Gmyl A.P., Korshenko S.A., Belousov E.V., Khitrina E.V., and Agol V.I. Nonreplicative homologous RNA recombination: promiscuous joining of RNA pieces?. RNA 9 10 (2003) 1221-1231
81. Gomez, J., Cacho, I., 2001. Can Nietzsche power relationships be experimentally approached with theoretical and viral quasispecies? Contributions to Science (Revista del Institut d'Estudis Catalans): http://www.cat-science.com 2 (1), 103-108.
82. Gomez J., Martell M., Quer J., Cabot B., and Esteban J.I. Hepatitis C viral quasispecies. J. Viral Hepat. 6 1 (1999) 3-16
83. González-López C., Arias A., Pariente N., Gómez-Mariano G., and Domingo E. Preextinction viral RNA can interfere with infectivity. J. Virol. 78 7 (2004) 3319-3324
84. Gonzalez-Peralta R.P., Qian K., She J.Y., Davis G.L., Ohno T., Mizokami M., and Lau J.Y. Clinical implications of viral quasispecies heterogeneity in chronic hepatitis C. J. Med. Virol. 49 3 (1996) 242-247
85. Goulder P., Price D., Nowak M., Rowland-Jones S., Phillips R., and McMichael A. Co-evolution of human immunodeficiency virus and cytotoxic T-lymphocyte responses. Immunol. Rev. 159 (1997) 17-29
86. Graci J.D., and Cameron C.E. Mechanisms of action of ribavirin against distinct viruses. Rev. Med. Virol. 16 1 (2006) 37-48
87. Grande-Pérez A., Lazaro E., Lowenstein P., Domingo E., and Manrubia S.C. Suppression of viral infectivity through lethal defection. Proc. Natl. Acad. Sci. U.S.A. 102 12 (2005) 4448-4452
88. Gratton S., Cheynier R., Dumaurier M.J., Oksenhendler E., and Wain-Hobson S. Highly restricted spread of HIV-1 and multiply infected cells within splenic germinal centers. Proc. Natl. Acad. Sci. U.S.A. 97 26 (2000) 14566-14571
89. Harris K.S., Brabant W., Styrchak S., Gall A., and Daifuku R. KP-1212/1461, a nucleoside designed for the treatment of HIV by viral mutagenesis. Antiviral Res. 67 1 (2005) 1-9
90. Hartwig D., Schutte C., Warnecke J., Dorn I., Hennig H., Kirchner H., and Schlenke P. The large form of ADAR 1 is responsible for enhanced hepatitis delta virus RNA editing in interferon-alpha-stimulated host cells. J. Viral. Hepat. 13 3 (2006) 150-157
91. Hayashi J., Kishihara Y., Yamaji K., Furusyo N., Yamamoto T., Pae Y., Etoh Y., Ikematsu H., and Kashiwagi S. Hepatitis C viral quasispecies and liver damage in patients with chronic hepatitis C virus infection. Hepatology 25 3 (1997) 697-701
92. Hohne M., Schreier E., and Roggendorf M. Sequence variability in the env-coding region of hepatitis C virus isolated from patients infected during a single source outbreak. Arch. Virol. 137 1-2 (1994) 25-34
93. Holland J. Transitions in understanding of RNA viruses: an historical perspective. Curr. Top. Microbiol. Immunol. 299 (2006) 371-401
94. Holland J.J., Spindler K., Horodyski F., Grabau E., Nichol S., and VandePol S. Rapid evolution of RNA genomes. Science 215 4540 (1982) 1577-1585
95. Holland J.J., de la Torre J.C., Steinhauer D.A., Clarke D., Duarte E., and Domingo E. Virus mutation frequencies can be greatly underestimated by monoclonal antibody neutralization of virions. J. Virol. 63 12 (1989) 5030-5036
96. Holland J.J., de La Torre J.C., and Steinhauer D.A. RNA virus populations as quasispecies. Curr. Top. Microbiol. Immunol. 176 (1992) 1-20
97. Honda M., Kaneko S., Sakai A., Unoura M., Murakami S., and Kobayashi K. Degree of diversity of hepatitis C virus quasispecies and progression of liver disease. Hepatology 20 5 (1994) 1144-1151
98. Hong Z. The role of ribavirin-induced mutagenesis in HCV therapy: a concept or a fact?. Hepatology 38 4 (2003) 807-810
99. Hsu H.Y., Chang M.H., Liaw S.H., Ni Y.H., and Chen H.L. Changes of hepatitis B surface antigen variants in carrier children before and after universal vaccination in Taiwan. Hepatology 30 5 (1999) 1312-1317
100. Imazeki F., Omata M., and Ohto M. Heterogeneity and evolution rates of delta virus RNA sequences. J. Virol. 64 11 (1990) 5594-5599
101. Isnard M., Granier M., Frutos R., Reynaud B., and Peterschmitt M. Quasispecies nature of three maize streak virus isolates obtained through different modes of selection from a population used to assess response to infection of maize cultivars. J. Gen. Virol. 79 (1998) 3091-3099
102. Jang S.J., Wang L.F., Radkowski M., Rakela J., and Laskus T. Differences between hepatitis C virus 5′ untranslated region quasispecies in serum and liver. J. Gen. Virol. 80 Pt 3 (1999) 711-716
103. Kalinina O., Norder H., Mukomolov S., and Magnius L.O. A natural intergenotypic recombinant of hepatitis C virus identified in St. Petersburg. J. Virol. 76 8 (2002) 4034-4043
104. Kamp C. A quasispecies approach to viral evolution in the context of an adaptive immune system. Microbes Infect. 5 15 (2003) 1397-1405
105. Kanazawa Y., Hayashi N., Mita E., Li T., Hagiwara H., Kasahara A., Fusamoto H., and Kamada T. Influence of viral quasispecies on effectiveness of interferon therapy in chronic hepatitis C patients. Hepatology 20 5 (1994) 1121-1130
106. Kanda T., Yokosuka O., Imazeki F., Tanaka M., Shino Y., Shimada H., Tomonaga T., Nomura F., Nagao K., Ochiai T., and Saisho H. Inhibition of subgenomic hepatitis C virus RNA in Huh-7 cells: ribavirin induces mutagenesis in HCV RNA. J. Viral. Hepat. 11 6 (2004) 479-487
107. Kawada M., Igarashi H., Takeda A., Tsukamoto T., Yamamoto H., Dohki S., Takiguchi M., and Matano T. Involvement of multiple epitope-specific cytotoxic T-lymphocyte responses in vaccine-based control of simian immunodeficiency virus replication in rhesus macaques. J. Virol. 80 4 (2006) 1949-1958
108. Keulen W., van Wijk A., Schuurman R., Berkhout B., and Boucher C.A. Increased polymerase fidelity of lamivudine-resistant HIV-1 variants does not limit their evolutionary potential. AIDS 13 11 (1999) 1343-1349
109. Kimata J.T., Kuller L., Anderson D.B., Dailey P., and Overbaugh J. Emerging cytopathic and antigenic simian immunodeficiency virus variants influence AIDS progression. Nat. Med. 5 5 (1999) 535-541
110. Koenig S., Conley A.J., Brewah Y.A., Jones G.M., Leath S., Boots L.J., Davey V., Pantaleo G., Demarest J.F., Carter C., et al. Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression. Nat. Med. 1 4 (1995) 330-336
111. Koizumi K., Enomoto N., Kurosaki M., Murakami T., Izumi N., Marumo F., and Sato C. Diversity of quasispecies in various disease stages of chronic hepatitis C virus infection and its significance in interferon treatment. Hepatology 22 1 (1995) 30-35
112. Kojima M., Osuga T., Tsuda F., Tanaka T., and Okamoto H. Influence of antibodies to the hypervariable region of E2/NS1 glycoprotein on the selective replication of hepatitis C virus in chimpanzees. Virology 204 2 (1994) 665-672
113. Kurosaki M., Enomoto N., Nouchi T., Sakuma I., Marumo F., and Sato C. Fraction-specific populations of the hypervariable region of the hepatitis C virus in a patient with cryoglobulinemia. J. Med. Virol. 46 4 (1995) 403-408
114. Lada O., Benhamou Y., Poynard T., and Thibault V. Coexistence of hepatitis B surface antigen (HBs Ag) and anti-HBs antibodies in chronic hepatitis B virus carriers: influence of "a" determinant variants. J. Virol. 80 6 (2006) 2968-2975
115. Lanford R.E., Chavez D., Guerra B., Lau J.Y., Hong Z., Brasky K.M., and Beames B. Ribavirin induces error-prone replication of GB virus B in primary tamarin hepatocytes. J. Virol. 75 17 (2001) 8074-8081
116. Laskus T., Wilkinson J., Gallegos-Orozco J.F., Radkowski M., Adair D.M., Nowicki M., Operskalski E., Buskell Z., Seeff L.B., Vargas H., and Rakela J. Analysis of hepatitis C virus quasispecies transmission and evolution in patients infected through blood transfusion. Gastroenterology 127 3 (2004) 764-776
117. Le Guen B., Squadrito G., Nalpas B., Berthelot P., Pol S., and Brechot C. Hepatitis C virus genome complexity correlates with response to interferon therapy: a study in French patients with chronic hepatitis C. Hepatology 25 5 (1997) 1250-1254
118. Lee C.M., Bih F.Y., Chao Y.C., Govindarajan S., and Lai M.M. Evolution of hepatitis delta virus RNA during chronic infection. Virology 188 1 (1992) 265-273
119. Leslie A.J., Pfafferott K.J., Chetty P., Draenert R., Addo M.M., Feeney M., Tang Y., Holmes E.C., Allen T., Prado J.G., Altfeld M., Brander C., Dixon C., Ramduth D., Jeena P., Thomas S.A., St John A., Roach T.A., Kupfer B., Luzzi G., Edwards A., Taylor G., Lyall H., Tudor-Williams G., Novelli V., Martinez-Picado J., Kiepiela P., Walker B.D., and Goulder P.J. HIV evolution: CTL escape mutation and reversion after transmission. Nat. Med. 10 3 (2004) 282-289
120. Loeb L.A., Essigmann J.M., Kazazi F., Zhang J., Rose K.D., and Mullins J.I. Lethal mutagenesis of HIV with mutagenic nucleoside analogs. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 1492-1497
121. López-Bueno A., Mateu M.G., and Almendral J.M. High mutant frequency in populations of a DNA virus allows evasion from antibody therapy in an immunodeficient host. J. Virol. 77 4 (2003) 2701-2708
122. López-Bueno A., Villarreal L.P., and Almendral J.M. Parvovirus variation for disease: A difference with RNA viruses?. Curr. Top. Microbiol. Immunol. 299 (2006)
123. Lopez-Labrador F.X., Ampurdanes S., Gimenez-Barcons M., Guilera M., Costa J., Jimenez de Anta M.T., Sanchez-Tapias J.M., Rodes J., and Saiz J.C. Relationship of the genomic complexity of hepatitis C virus with liver disease severity and response to interferon in patients with chronic HCV genotype 1b infection [correction of interferon]. Hepatology 29 3 (1999) 897-903
124. Lu L., Nakano T., Orito E., Mizokami M., and Robertson B.H. Evaluation of accumulation of hepatitis C virus mutations in a chronically infected chimpanzee: comparison of the core, E1, HVR1, and NS5b regions. J. Virol. 75 6 (2001) 3004-3009
125. Maag D., Castro C., Hong Z., and Cameron C.E. Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin. J. Biol. Chem. 276 49 (2001) 46094-46098
126. Maggi F., Fornai C., Vatteroni M.L., Giorgi M., Morrica A., Pistello M., Cammarota G., Marchi S., Ciccorossi P., Bionda A., and Bendinelli M. Differences in hepatitis C virus quasispecies composition between liver, peripheral blood mononuclear cells and plasma. J. Gen. Virol. 78 Pt 7 (1997) 1521-1525
127. Mansky L.M., Le Rouzic E., Benichou S., and Gajary L.C. Influence of reverse transcriptase variants, drugs, and Vpr on human immunodeficiency virus type 1 mutant frequencies. J. Virol. 77 3 (2003) 2071-2080
128. Marcus P.I., Rodriguez L.L., and Sekellick M.J. Interferon induction as a quasispecies marker of vesicular stomatitis virus populations. J. Virol. 72 1 (1998) 542-549
129. Margeridon S., Lachaux A., Trepo C., Zoulim F., and Kay A. A quasi-monoclonal anti-HBs response can lead to immune escape of 'wild-type' hepatitis B virus. J. Gen. Virol. 86 Pt6 (2005) 1687-1693
130. Martell M., Esteban J.I., Quer J., Genesca J., Weiner A., Esteban R., Guardia J., and Gomez J. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J. Virol. 66 5 (1992) 3225-3229
131. Martin V., Perales C., Davila M., and Domingo E. Viral fitness can influence the repertoire of virus variants selected by antibodies. J. Mol. Biol. 362 (2006) 44-54
132. Martinot-Peignoux M., Marcellin P., Pouteau M., Castelnau C., Boyer N., Poliquin M., Degott C., Descombes I., Le Breton V., Milotova V., et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 22 4 Pt 1 (1995) 1050-1056
133. Mas A., Ulloa E., Bruguera M., Furcic I., Garriga D., Fabregas S., Andreu D., Saiz J.C., and Diez J. Hepatitis C virus population analysis of a single-source nosocomial outbreak reveals an inverse correlation between viral load and quasispecies complexity. J. Gen. Virol. 85 Pt 12 (2004) 3619-3626
134. Matsumori A., Yutani C., Ikeda Y., Kawai S., and Sasayama S. Hepatitis C virus from the hearts of patients with myocarditis and cardiomyopathy. Lab. Invest. 80 7 (2000) 1137-1142
135. Matsumori A., Shimada T., Chapman N.M., Tracy S.M., and Mason J.W. Myocarditis and heart failure associated with hepatitis C virus infection. J. Card. Fail 12 4 (2006) 293-298
136. Mayr E. Driving forces in evolution. An analysis of natural selection. In: Morse S.S. (Ed). The Evolutionary Biology of Viruses (1994), Raven Press, New York
137. Menéndez-Arias L. Molecular basis of fidelity of DNA synthesis and nucleotide specificity of retroviral reverse transcriptases. Prog. Nucl. Acid Res. Mol. Biol. 71 (2002) 91-147
138. Menéndez-Arias L. Targeting HIV: antiretroviral therapy and development of drug resistance. Trends Pharmacol. Sci. 23 8 (2002) 381-388
139. Minskaia E., Hertzig T., Gorbalenya A.E., Campanacci V., Cambillau C., Canard B., and Ziebuhr J. Discovery of an RNA virus 3′ → 5′ exoribonuclease that is critically involved in coronavirus RNA synthesis. Proc. Natl. Acad. Sci. U.S.A. 103 13 (2006) 5108-5113
140. Mongkolsapaya J., Dejnirattisai W., Xu X.N., Vasanawathana S., Tangthawornchaikul N., Chairunsri A., Sawasdivorn S., Duangchinda T., Dong T., Rowland-Jones S., Yenchitsomanus P.T., McMichael A., Malasit P., and Screaton G. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat. Med. 9 7 (2003) 921-927
141. Mongkolsapaya J., Duangchinda T., Dejnirattisai W., Vasanawathana S., Avirutnan P., Jairungsri A., Khemnu N., Tangthawornchaikul N., Chotiyarnwong P., Sae-Jang K., Koch M., Jones Y., McMichael A., Xu X., Malasit P., and Screaton G. T cell responses in dengue hemorrhagic fever: are cross-reactive T cells suboptimal?. J. Immunol. 176 6 (2006) 3821-3829
142. Moreno I.M., Malpica J.M., Rodriguez-Cerezo E., and Garcia-Arenal F. A mutation in tomato aspermy cucumovirus that abolishes cell-to-cell movement is maintained to high levels in the viral RNA population by complementation. J. Virol. 71 12 (1997) 9157-9162
143. Morishima C., Polyak S.J., Ray R., Doherty M.C., Di Bisceglie A.M., Malet P.F., Bonkovsky H.L., Sullivan D.G., Gretch D.R., Rothman A.L., Koziel M.J., and Lindsay K.L. Hepatitis C virus-specific immune responses and quasi-species variability at baseline are associated with nonresponse to antiviral therapy during advanced hepatitis C. J. Infect. Dis. 193 7 (2006) 931-940
144. Naegeli, H. (1997) Mechanisms of DNA damage recognition in mammalian cells. Landes Bioscience, Austin, Texas.
145. Nagy P.D., and Simon A.E. New insights into the mechanisms of RNA recombination. Virology 235 (1997) 1-9
146. Naito M., Hayashi N., Hagiwara H., Hiramatsu N., Kasahara A., Fusamoto H., and Kamada T. Serum hepatitis C virus RNA quantity and histological features of hepatitis C virus carriers with persistently normal ALT levels. Hepatology 19 4 (1994) 871-875
147. Nájera I., Holguín A., Quiñones-Mateu M.E., Muñoz-Fernández M.A., Nájera R., López-Galíndez C., and Domingo E. Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy. J. Virol. 69 1 (1995) 23-31
148. Nakao H., Okamoto H., Fukuda M., Tsuda F., Mitsui T., Masuko K., Iizuka H., Miyakawa Y., and Mayumi M. Mutation rate of GB virus C/hepatitis G virus over the entire genome and in subgenomic regions. Virology 233 1 (1997) 43-50
149. Neumann A.U., Lam N.P., Dahari H., Gretch D.R., Wiley T.E., Layden T.J., and Perelson A.S. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282 5386 (1998) 103-107
150. Neyts J. Selective inhibitors of hepatitis C virus replication. Antiviral Res. 71 2-3 (2006) 363-371
151. Nijhuis M., Schuurman R., de Jong D., Erickson J., Gustchina E., Albert J., Schipper P., Gulnik S., and Boucher C.A. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS 13 17 (1999) 2349-2359
152. Noguchi C., Ishino H., Tsuge M., Fujimoto Y., Imamura M., Takahashi S., and Chayama K. G to A hypermutation of hepatitis B virus. Hepatology 41 3 (2005) 626-633
153. Noppornpanth S., Lien T.X., Poovorawan Y., Smits S.L., Osterhaus A.D., and Haagmans B.L. Identification of a naturally occurring recombinant genotype 2/6 hepatitis C virus. J. Virol. 80 15 (2006) 7569-7577
154. Nousbaum J., Polyak S.J., Ray S.C., Sullivan D.G., Larson A.M., Carithers Jr. R.L., and Gretch D.R. Prospective characterization of full-length hepatitis C virus NS5A quasispecies during induction and combination antiviral therapy. J. Virol. 74 19 (2000) 9028-9038
155. Novella I.S. Contributions of vesicular stomatitis virus to the understanding of RNA virus evolution. Curr. Opin. Microbiol. 6 4 (2003) 399-405
156. Novella I.S., Quer J., Domingo E., and Holland J.J. Exponential fitness gains of RNA virus populations are limited by bottleneck effects. J. Virol. 73 2 (1999) 1668-1671
157. Nowak M., and Schuster P. Error thresholds of replication in finite populations mutation frequencies and the onset of Muller's ratchet. J. Theor. Biol. 137 4 (1989) 375-395
158. Nowak M.A., Anderson R.M., McLean A.R., Wolfs T.F., Goudsmit J., and May R.M. Antigenic diversity thresholds and the development of AIDS. Science 254 5034 (1991) 963-969
159. Núñez J.I., Baranowski E., Molina N., Ruiz-Jarabo C.M., Sánchez C., Domingo E., and Sobrino F. A single amino acid substitution in nonstructural protein 3A can mediate adaptation of foot-and-mouth disease virus to the guinea pig. J. Virol. 75 8 (2001) 3977-3983
160. Ogata N., Alter H.J., Miller R.H., and Purcell R.H. Nucleotide sequence and mutation rate of the H strain of hepatitis C virus. Proc. Natl. Acad. Sci. U.S.A 88 8 (1991) 3392-3396
161. Okada S., Akahane Y., Suzuki H., Okamoto H., and Mishiro S. The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients. Hepatology 16 3 (1992) 619-624
162. Okamoto H., Kojima M., Okada S., Yoshizawa H., Iizuka H., Tanaka T., Muchmore E.E., Peterson D.A., Ito Y., and Mishiro S. Genetic drift of hepatitis C virus during an 8.2-year infection in a chimpanzee: variability and stability. Virology 190 2 (1992) 894-899
163. Page K.M., and Nowak M.A. Unifying evolutionary dynamics. J. Theor. Biol. 219 1 (2002) 93-98
164. Pal S., Sullivan D.G., Kim S., Lai K.K., Kae J., Cotler S.J., Carithers Jr. R.L., Wood B.L., Perkins J.D., and Gretch D.R. Productive replication of hepatitis C virus in perihepatic lymph nodes in vivo: implications of HCV lymphotropism. Gastroenterology 130 4 (2006) 1107-1116
165. Pallier C., Castera L., Soulier A., Hezode C., Nordmann P., Dhumeaux D., and Pawlotsky J.M. Dynamics of hepatitis B virus resistance to lamivudine. J. Virol. 80 2 (2006) 643-653
166. Pariente N., Airaksinen A., and Domingo E. Mutagenesis versus inhibition in the efficiency of extinction of foot-and-mouth disease virus. J. Virol. 77 12 (2003) 7131-7138
167. Parker W.B. Metabolism and antiviral activity of ribavirin. Virus Res. 107 2 (2005) 165-171
168. Parrish C.R., and Kawaoka Y. The origins of new pandemic viruses: the acquisition of new host ranges by canine parvovirus and influenza A viruses. Annu. Rev. Microbiol. 59 (2005) 553-586
169. Pawlotsky J.M. Hepatitis C virus resistance to antiviral therapy. Hepatology 32 5 (2000) 889-896
170. Pawlotsky J.M. Mechanisms of antiviral treatment efficacy and failure in chronic hepatitis C. Antiviral Res. 59 1 (2003) 1-11
171. Pawlotsky J.M. Hepatitis C virus population dynamics during infection. Curr. Top. Microbiol. Immunol. 299 (2006) 261-284
172. Pfeiffer J.K., and Kirkegaard K. A single mutation in poliovirus RNA-dependent RNA polymerase confers resistance to mutagenic nucleotide analogs via increased fidelity. Proc. Natl. Acad. Sci. U.S.A. 100 12 (2003) 7289-7294
173. Pfeiffer J.K., and Kirkegaard K. Increased fidelity reduces poliovirus fitness under selective pressure in mice. PLoS Pathogens 1 (2005) 102-110
174. Polyak S.J., Faulkner G., Carithers Jr. R.L., Corey L., and Gretch D.R. Assessment of hepatitis C virus quasispecies heterogeneity by gel shift analysis: correlation with response to interferon therapy. J. Infect. Dis. 175 5 (1997) 1101-1107
175. Poynard T., Marcellin P., Lee S.S., Niederau C., Minuk G.S., Ideo G., Bain V., Heathcote J., Zeuzem S., Trepo C., and Albrecht J. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 352 9138 (1998) 1426-1432
176. Puig-Basagoiti F., Saiz J.C., Forns X., Ampurdanes S., Gimenez-Barcons M., Franco S., Sanchez-Fueyo A., Costa J., Sanchez-Tapias J.M., and Rodes J. Influence of the genetic heterogeneity of the ISDR and PePHD regions of hepatitis C virus on the response to interferon therapy in chronic hepatitis C. J. Med. Virol. 65 1 (2001) 35-44
177. Qin H., Shire N.J., Keenan E.D., Rouster S.D., Eyster M.E., Goedert J.J., Koziel M.J., and Sherman K.E. HCV quasispecies evolution: association with progression to end-stage liver disease in hemophiliacs infected with HCV or HCV/HIV. Blood 105 2 (2005) 533-541
178. Quer J., Murillo P., Martell M., Gomez J., Esteban J.I., Esteban R., and Guardia J. Subtype mutations in the envelope 2 region including phosphorylation homology domain of hepatitis C virus do not predict effectiveness of antiviral therapy. J. Viral Hepat. 11 1 (2004) 45-54
179. Quer J., Esteban J.I., Cos J., Sauleda S., Ocana L., Martell M., Otero T., Cubero M., Palou E., Murillo P., Esteban R., and Guardia J. Effect of bottlenecking on evolution of the nonstructural protein 3 gene of hepatitis C virus during sexually transmitted acute resolving infection. J. Virol. 79 24 (2005) 15131-15141
180. Quiñones-Mateu M.E., and Arts E. Virus fitness: concept, qunatification, and application to HIV population dynamics. Curr. Top. Microbiol. Immunol. 299 (2006) 83-140
181. Qureshi, S.A., 2006. Hepatitis C virus-biology, host evasion strategies, and promising new therapies on the horizon. Med. Res. Rev., in press.
182. Regoes R.R., and Bonhoeffer S. Emergence of drug-resistant influenza virus: population dynamical considerations. Science 312 5772 (2006) 389-391
183. Rehermann B., and Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat. Rev. Immunol. 5 3 (2005) 215-229
184. Roque-Afonso A.M., Ducoulombier D., Di Liberto G., Kara R., Gigou M., Dussaix E., Samuel D., and Feray C. Compartmentalization of hepatitis C virus genotypes between plasma and peripheral blood mononuclear cells. J. Virol. 79 10 (2005) 6349-6357
185. Rothman A.L., Morishima C., Bonkovsky H.L., Polyak S.J., Ray R., Di Bisceglie A.M., Lindsay K.L., Malet P.F., Chang M., Gretch D.R., Sullivan D.G., Bhan A.K., Wright E.C., and Koziel M.J. Associations among clinical, immunological, and viral quasispecies measurements in advanced chronic hepatitis C. Hepatology 41 3 (2005) 617-625
186. Roux L., Simon A.E., and Holland J.J. Effects of defective interfering viruses on virus replication and pathogenesis in vitro and in vivo. Adv. Virus Res. 40 (1991) 181-211
187. Rowe C.L., Baker S.C., Nathan M.J., and Fleming J.O. Evolution of mouse hepatitis virus: detection and characterization of spike deletion variants during persistent infection. J. Virol. 71 4 (1997) 2959-2969
188. Ruiz-Jarabo C.M., Arias A., Baranowski E., Escarmís C., and Domingo E. Memory in viral quasispecies. J. Virol. 74 (2000) 3543-3547
189. Ruiz-Jarabo C.M., Ly C., Domingo E., and de la Torre J.C. Lethal mutagenesis of the prototypic arenavirus lymphocytic choriomeningitis virus (LCMV). Virology 308 1 (2003) 37-47
190. Saakian D.B., and Hu C.K. Exact solution of the Eigen model with general fitness functions and degradation rates. Proc. Natl. Acad. Sci. U.S.A. 103 13 (2006) 4935-4939
191. Saiz J.C., Lopez-Labrador F.X., Ampurdanes S., Dopazo J., Forns X., Sanchez-Tapias J.M., and Rodes J. The prognostic relevance of the nonstructural 5A gene interferon sensitivity determining region is different in infections with genotype 1b and 3a isolates of hepatitis C virus. J. Infect. Dis. 177 4 (1998) 839-847
192. Sánchez G., Bosch A., Gómez-Mariano G., Domingo E., and Pinto R. Evidence for quasispecies distributions in the human hepatitis A virus genome. Virology 315 (2003) 34-42
193. Sánchez G., Bosch A., and Pinto R.M. Genome variability and capsid structural constraints of hepatitis a virus. J. Virol. 77 1 (2003) 452-459
194. Sato S., Wong S.K., and Lazinski D.W. Hepatitis delta virus minimal substrates competent for editing by ADAR1 and ADAR2. J. Virol. 75 18 (2001) 8547-8555
195. Schaub M., and Keller W. RNA editing by adenosine deaminases generates RNA and protein diversity. Biochimie 84 8 (2002) 791-803
196. Serviene E., Shapka N., Cheng C.P., Panavas T., Phuangrat B., Baker J., and Nagy P.D. Genome-wide screen identifies host genes affecting viral RNA recombination. Proc. Natl. Acad. Sci. U.S.A. 102 30 (2005) 10545-10550
197. Sheehy A.M., Gaddis N.C., Choi J.D., and Malim M.H. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418 6898 (2002) 646-650
198. Smith D.B., Pathirana S., Davidson F., Lawlor E., Power J., Yap P.L., and Simmonds P. The origin of hepatitis C virus genotypes. J. Gen. Virol. 78 (1997) 321-328
199. Solé R.V., Sardanyes J., Diez J., and Mas A. Information catastrophe in RNA viruses through replication thresholds. J. Theor. Biol. 240 3 (2006) 353-359
200. Squadrito G., Leone F., Sartori M., Nalpas B., Berthelot P., Raimondo G., Pol S., and Brechot C. Mutations in the nonstructural 5A region of hepatitis C virus and response of chronic hepatitis C to interferon alfa. Gastroenterology 113 2 (1997) 567-572
201. Steinhauer D.A., Domingo E., and Holland J.J. Lack of evidence for proofreading mechanisms associated with an RNA virus polymerase. Gene 122 2 (1992) 281-288
202. Steitz T.A. DNA polymerases: structural diversity and common mechanisms. J. Biol. Chem. 274 25 (1999) 17395-17398
203. Suspene R., Guetard D., Henry M., Sommer P., Wain-Hobson S., and Vartanian J.P. Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo. Proc. Natl. Acad. Sci. U.S.A. 102 23 (2005) 8321-8326
204. Suspene R., Henry M., Guillot S., Wain-Hobson S., and Vartanian J.P. Recovery of APOBEC3-edited human immunodeficiency virus G → A hypermutants by differential DNA denaturation PCR. J. Gen. Virol. 86 Pt 1 (2005) 125-129
205. Swetina J., and Schuster P. Self-replication with errors. A model for polynucleotide replication. Biophys. Chem. 16 4 (1982) 329-345
206. Tai P.C., Banik D., Lin G.I., Pai S., Pai K., Lin M.H., Yuoh G., Che S., Hsu S.H., Chen T.C., Kuo T.T., Lee C.S., Yang C.S., and Shih C. Novel and frequent mutations of hepatitis B virus coincide with a major histocompatibility complex class I-restricted T-cell epitope of the surface antigen. J. Virol. 71 6 (1997) 4852-4856
207. Taylor D.R., Shi S.T., Romano P.R., Barber G.N., and Lai M.M. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 285 5424 (1999) 107-110
208. Thimme R., Bukh J., Spangenberg H.C., Wieland S., Pemberton J., Steiger C., Govindarajan S., Purcell R.H., and Chisari F.V. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc. Natl. Acad. Sci. U.S.A. 99 24 (2002) 15661-15668
209. Timm J., Lauer G.M., Kavanagh D.G., Sheridan I., Kim A.Y., Lucas M., Pillay T., Ouchi K., Reyor L.L., Schulze zur Wiesch J., Gandhi R.T., Chung R.T., Bhardwaj N., Klenerman P., Walker B.D., and Allen T.M. CD8 epitope escape and reversion in acute HCV infection. J. Exp. Med. 200 12 (2004) 1593-1604
210. Tracy S., Chapman N.M., Drescher K.M., Kono K., and Tapprich W. Evolution of virulence in picornaviruses. Curr. Top. Microbiol. Immunol. 299 (2006) 193-209
211. Valente L., and Nishikura K. ADAR gene family and A-to-I RNA editing: diverse roles in posttranscriptional gene regulation. Prog. Nucleic Acid Res. Mol. Biol. 79 (2005) 299-338
212. Vignuzzi M., Stone J.K., Arnold J.J., Cameron C.E., and Andino R. Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population. Nature 439 (2006) 344-348
213. Vo N.V., Young K.C., and Lai M.M.C. Mutagenic and inhibitory effects of ribavirin on hepatitis C virus RNA polymerase. Biochemistry 42 35 (2003) 10462-10471
214. Wang T.C., and Chao M. RNA recombination of hepatitis delta virus in natural mixed-genotype infection and transfected cultured cells. J. Virol. 79 4 (2005) 2221-2229
215. Weiner A., Erickson A.L., Kansopon J., Crawford K., Muchmore E., Hughes A.L., Houghton M., and Walker C.M. Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant. Proc. Natl. Acad. Sci. U.S.A. 92 7 (1995) 2755-2759
216. Wilke C.O. Quasispecies theory in the context of population genetics. BMC Evol. Biol. 5 (2005) 44
217. Wilke C.O., Ronnewinkel C., and Martinetz T. Dynamic fitness landscapes in molecular evolution. Physics Reports 349 (2001) 395-446
218. Wyatt C.A., Andrus L., Brotman B., Huang F., Lee D.H., and Prince A.M. Immunity in chimpanzees chronically infected with hepatitis C virus: role of minor quasispecies in reinfection. J. Virol. 72 3 (1998) 1725-1730
219. Yamamoto K., Horikita M., Tsuda F., Itoh K., Akahane Y., Yotsumoto S., Okamoto H., Miyakawa Y., and Mayumi M. Naturally occurring escape mutants of hepatitis B virus with various mutations in the S gene in carriers seropositive for antibody to hepatitis B surface antigen. J. Virol. 68 4 (1994) 2671-2676
220. Yang J., Xing K., Deng R., Wang J., and Wang X. Identification of Hepatitis B virus putative intergenotype recombinants by using fragment typing. J. Gen. Virol. 87 Pt 8 (2006) 2203-2215
221. Yeo A.E., Ghany M., Conry-Cantilena C., Melpolder J.C., Kleiner D.E., Shih J.W., Hoofnagle J.H., and Alter H.J. Stability of HCV-RNA level and its lack of correlation with disease severity in asymptomatic chronic hepatitis C virus carriers. J. Viral. Hepat. 8 4 (2001) 256-263
222. Young K.C., Lindsay K.L., Lee K.J., Liu W.C., He J.W., Milstein S.L., and Lai M.M. Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy. Hepatology 38 4 (2003) 869-878
223. Yuki N., Hayashi N., Moribe T., Matsushita Y., Tabata T., Inoue T., Kanazawa Y., Ohkawa K., Kasahara A., Fusamoto H., and Kamada T. Relation of disease activity during chronic hepatitis C infection to complexity of hypervariable region 1 quasispecies. Hepatology 25 2 (1997) 439-444
224. Zhou S., Liu R., Baroudy B.M., Malcolm B.A., and Reyes G.R. The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA. Virology 310 2 (2003) 333-342